Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.19, sa.2, ss.131-133, 2011 (Scopus)
A 20-year-old male with Best's vitelliform macular dystrophy complained of decreased vision in the left eye for the previous 1 month. He was evaluated by complete ophthalmologic examination, fluorescein angiography (FA), fundus autofluorescence (FAF), and optical coherence tomography(OCT). Best corrected visual acuity (BCVA) was 5/10 in the left eye and the fundus examination revealed a vitelliruptive lesion with hemorrhage in the left eye. The hemorrhage was thought to be a manifestation of the vitelliruptive stage and no treatment was implemented. After 3 months, visual acuity decreased in the right eye. Best corrected visual acuity was counting fingers at 2 meters in the right eye and 10/10 in the left eye. The fundus examination revealed macular edema and hemorrhage in the right eye. FA disclosed increased leakage due to choroidal neovascularization (CNV). OCT demonstrated increased hyperreflectivity in the subfoveal area with distinctive fluid and intraretinal edema. Three doses of intravitreal ranibizumab were applied at monthly intervals. Best corrected visual acuity improved to 3/10 and 10/10 one month and 6 months after the injections, respectively. CNV is a rare complication in Best's vitelliform macular dystrophy. Although the histopathologic data are not clear, one may hypothesize that vascular endothelial growth factor (VEGF) plays a role in the pathogenesis of CNV secondary to vitelliform dystrophy. Intravitreal ranibizumab as an anti-VEGF agent may be a new approach for the therapy of CNV in Best's vitelliform macular dystrophy.